Clinical Trial

CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

Name: CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA — clinical trial record (NCT07558434)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aimed to explore the efficacy and safety of cyclosporine (CsA) +eltrombopag (EPAG)/hetrombopag (HPAG)+romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)

Trial Details

NCT Number	NCT07558434
Lead Sponsor	Peking Union Medical College Hospital
Conditions	Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia
Enrollment	43 participants
Start Date	2026-04
Primary Completion	2028-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-30